NASDAQ:ATNX - Athenex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.84 -0.21 (-1.49 %) (As of 05/23/2019 04:00 PM ET)Previous Close$14.05Today's Range$13.61 - $14.1352-Week Range$9.38 - $20.90Volume310,500 shsAverage Volume324,515 shsMarket Capitalization$928.19 millionP/E RatioN/ADividend YieldN/ABeta0.03 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York. Receive ATNX News and Ratings via Email Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATNX Previous Symbol CUSIPN/A CIK1300699 Webhttp://www.athenex.com/ Phone716-427-2950Debt Debt-to-Equity Ratio0.57 Current Ratio2.22 Quick Ratio1.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$89.10 million Price / Sales10.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book9.68Profitability EPS (Most Recent Fiscal Year)($1.44) Net Income$-117,440,000.00 Net Margins-189.86% Return on Equity-96.55% Return on Assets-55.38%Miscellaneous Employees575 Outstanding Shares67,066,000Market Cap$928.19 million Next Earnings Date8/13/2019 (Estimated) OptionableOptionable Athenex (NASDAQ:ATNX) Frequently Asked Questions What is Athenex's stock symbol? Athenex trades on the NASDAQ under the ticker symbol "ATNX." How were Athenex's earnings last quarter? Athenex Inc (NASDAQ:ATNX) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.08. The company earned $25.31 million during the quarter, compared to analysts' expectations of $19.55 million. Athenex had a negative return on equity of 96.55% and a negative net margin of 189.86%. View Athenex's Earnings History. When is Athenex's next earnings date? Athenex is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Athenex. What price target have analysts set for ATNX? 6 analysts have issued 1 year target prices for Athenex's stock. Their forecasts range from $15.00 to $27.00. On average, they expect Athenex's stock price to reach $20.40 in the next year. This suggests a possible upside of 47.4% from the stock's current price. View Analyst Price Targets for Athenex. What is the consensus analysts' recommendation for Athenex? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athenex. Has Athenex been receiving favorable news coverage? Media headlines about ATNX stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Athenex earned a news impact score of 0.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of Athenex's key competitors? Some companies that are related to Athenex include ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Amneal Pharmaceuticals (AMRX), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO) and Uniqure (QURE). What other stocks do shareholders of Athenex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Exelixis (EXEL), Portola Pharmaceuticals (PTLA), Anavex Life Sciences (AVXL), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Amicus Therapeutics (FOLD), Gilead Sciences (GILD) and Madrigal Pharmaceuticals (MDGL). Who are Athenex's key executives? Athenex's management team includes the folowing people: Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 59)Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 70)Dr. Rudolf Kwan M.D., M.B., B.S., Exec. VP & Chief Medical Officer (Age 66)Mr. Kam-Chung Leung GBS, LLD, OBE, JP, Strategic & Bus. Advisor (Age 67)Dr. Allen Barnett, Co-Founder & Pres Emeritus When did Athenex IPO? (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager. Who are Athenex's major shareholders? Athenex's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.34%), Hsbc Holdings PLC (1.46%), J. Goldman & Co LP (1.13%), Northern Trust Corp (0.80%), Geode Capital Management LLC (0.80%) and HighTower Advisors LLC (0.54%). Company insiders that own Athenex stock include Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Sheldon Trainor-Degirolamo, Song-Yi Zhang and William Wei Zuo. View Institutional Ownership Trends for Athenex. Which institutional investors are selling Athenex stock? ATNX stock was sold by a variety of institutional investors in the last quarter, including Natixis, Citigroup Inc., Morgan Stanley, BlackRock Inc., JPMorgan Chase & Co., Strs Ohio, Northern Trust Corp and California State Teachers Retirement System. Company insiders that have sold Athenex company stock in the last year include Sheldon Trainor-Degirolamo and Song-Yi Zhang. View Insider Buying and Selling for Athenex. Which institutional investors are buying Athenex stock? ATNX stock was purchased by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, Emory University, Schonfeld Strategic Advisors LLC, First Trust Advisors LP, Hsbc Holdings PLC, J. Goldman & Co LP, Geode Capital Management LLC and ArrowMark Colorado Holdings LLC. Company insiders that have bought Athenex stock in the last two years include Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Song-Yi Zhang and William Wei Zuo. View Insider Buying and Selling for Athenex. How do I buy shares of Athenex? Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Athenex's stock price today? One share of ATNX stock can currently be purchased for approximately $13.84. How big of a company is Athenex? Athenex has a market capitalization of $928.19 million and generates $89.10 million in revenue each year. The company earns $-117,440,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Athenex employs 575 workers across the globe. What is Athenex's official website? The official website for Athenex is http://www.athenex.com/. How can I contact Athenex? Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950. MarketBeat Community Rating for Athenex (NASDAQ ATNX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 199 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 393MarketBeat's community ratings are surveys of what our community members think about Athenex and other stocks. Vote "Outperform" if you believe ATNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What is the LIBOR? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.